First‐in‐human trial of the PI3Kβ‐selective inhibitor SAR260301 in patients with advanced solid tumors
Philippe L. Bédard(Princess Margaret Cancer Centre), Keith T. Flaherty(Massachusetts General Hospital)
Cited by 34
Related Papers
Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial
|Genome Medicine|2016|283
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors
|JCI Insight|2018|147
A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors
|Investigational New Drugs|2013|56